https://www.selleckchem.com/pr....oducts/isa-2011b.htm
An amendment to this paper has been published and can be accessed via a link at the top of the paper.Immuno-oncology approaches have entered clinical practice, with tremendous progress particularly in the field of T cell-engaging therapies over the past decade. Herein, we provide an overview of the current status of bispecific T cell engager (BiTE) therapy, considering the unprecedented new indication for such therapy in combating minimal (or measurable) residual disease in patients with acute lymphoblastic leukaemia, and the developm
Like
Comment
Share
